RECURRENT GLIOBLASTOMA

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…

This Phase 3 trial tests a device called SonoCloud-9, which uses ultrasound to temporarily open the blood-brain barrier, allowing more carboplatin chemotherapy to reach glioblastoma tumors that have returned after initial treatment. About 560 participants will be randomly assigne…

This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to …

This early study tests a device called TheraSphere GBM in 36 people whose glioblastoma has come back after prior treatment. The device delivers tiny radioactive beads directly to the tumor to try to control it. The main goal is to check if the procedure is safe, not yet whether i…

This early-phase trial is testing whether sitagliptin, a drug used for diabetes, can help treat recurrent grade 4 glioma (a severe brain cancer) when combined with the standard drug bevacizumab. The study involves 45 adults whose cancer has returned after initial treatment. Resea…

This study is testing a new way to treat glioblastoma, an aggressive brain cancer that has come back after initial treatment. Doctors will place tiny devices that release a special type of radiation directly into the tumor. The goal is to see if this approach is safe and possible…

This early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to canc…

This early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. …

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This Phase 2 trial tests a two-part treatment for people with recurrent high-grade gliomas, a serious brain cancer. The treatment uses a virus (DB107-RRV) injected into the tumor and a chemotherapy pill (DB107-FC) taken by mouth. The goal is to shrink tumors and slow disease prog…

This early-stage trial tests whether RNA-lipid particle vaccines can be safely made and given to adults with recurrent glioblastoma, an aggressive brain cancer. The vaccines are designed to teach the immune system to attack tumor cells. The study will enroll 24 participants and f…

This early-phase study tests a new treatment for a type of brain cancer (glioblastoma) that has come back after standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The main goal is to check the safet…

This phase 2 trial tests two drugs, pumitamig and bevacizumab, alone or together with temozolomide, in 75 adults whose glioblastoma has returned after standard treatment. The goal is to see if these combinations can shrink tumors and control the disease. Participants will receive…

This pilot study tests a new approach called sonodynamic therapy for people with recurrent glioblastoma, a type of brain cancer that has come back. The treatment combines an investigational drug (5-ALA) with low-intensity focused ultrasound to target and damage tumor cells before…

This early-phase trial tests a new treatment for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment uses a patient's own immune cells (NK cells) that have been engineered in a lab to better recognize and attack tumor cells. The cells are delivered dire…

This phase 2 trial is testing whether giving one dose of the immunotherapy drug atezolizumab before surgery can help people with recurrent glioblastoma, a type of aggressive brain cancer. The main goal is to find biological markers (like tumor mutation burden) that predict who mi…

This early-stage study tests a new drug called YSCH-01, alone or with another drug (atezolizumab), in 10 people whose glioblastoma brain tumor has come back. The main goals are to check safety and see how many patients are alive after one year. Participants must be in fairly good…

This early-stage trial is testing a specially designed herpes virus, MVR-C5252, that is injected directly into brain tumors in people whose high-grade glioma has returned. The virus is modified to attack cancer cells and boost the immune system. The main goal is to see if it is s…

This study tests a drug called sacituzumab govitecan in 32 adults whose glioblastoma (a type of brain cancer) has returned after standard treatment. The drug targets a protein called Trop-2 found on tumor cells. The main goal is to see if patients live longer compared to past res…

This early-stage trial tests a new approach for people with recurrent glioblastoma, a fast-growing brain tumor. Doctors take immune cells called NK cells, engineer them to recognize and attack tumor cells, and deliver them directly into the brain. The study will check safety and …

This early-stage trial tests a new treatment for glioblastoma, an aggressive brain cancer. Researchers take a patient's own immune cells, modify them in the lab to better recognize and attack the tumor, and then infuse them back. The study involves 20 adults whose tumors have a s…

This early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…

This early-phase trial tests an experimental drug called CUE-102 in 18 adults with recurrent glioblastoma, a type of brain cancer that has come back. The drug is a fusion protein designed to help the immune system attack cancer cells. The main goal is to find a safe dose and chec…

This phase 2 trial tests a combination of three drugs—pembrolizumab (immunotherapy), olaparib (a targeted therapy), and temozolomide (chemotherapy)—in people with recurrent glioblastoma, a type of brain tumor that has come back after initial treatment. The study will enroll 78 ad…

This early-phase trial tests a new treatment for glioblastoma that has come back or is getting worse. The therapy combines a drug called 5-ALA with focused ultrasound waves to target and kill tumor cells without surgery. Eight adults with recurrent glioblastoma will receive the t…

This early-stage trial is testing a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a serious brain cancer that has come back. The treatment uses a patient's own immune cells that are modified in a lab to better recognize and attack the cancer. The main go…

This phase 2 trial tests the safety and feasibility of combining three treatments—tumor-treating electric fields (Optune GIO), MRI-guided laser ablation (NeuroBlate), and the immunotherapy drug pembrolizumab (Keytruda)—in 20 adults with recurrent glioblastoma. Participants receiv…

This early-phase trial is testing a new type of immunotherapy called CAR-T cells in 14 people with glioblastoma that has come back or not responded to treatment. The CAR-T cells are designed to target two proteins found on glioblastoma cells and are given directly into the fluid …

This early-phase trial tests the drug troriluzole in 27 adults with recurrent IDH wild-type glioblastoma, an aggressive brain cancer. Participants take the drug before surgery, and researchers measure brain activity and glutamate levels in the removed tumor tissue. The goal is to…

This study looks at how much of the drug T-DXd enters brain tumors in people with HER2-positive brain cancers or glioblastoma. Thirty participants will receive T-DXd before surgery to remove a brain tumor, and researchers will measure drug levels in the tumor. The goal is to see …

This pilot study uses two types of PET scans and a powerful 7Tesla MRI to create a detailed metabolic picture of glioblastoma, an aggressive brain cancer. Researchers will compare scan results with tumor tissue analysis to better understand how the tumor uses energy. The goal is …

This study looks at whether MRI scans and a protein called decorin can help identify which glioblastoma patients might benefit from a drug called bevacizumab. Researchers will collect tissue samples from 50 patients during surgery and compare them with MRI images. The goal is to …